Riskpilot← Back to searchSign inGet full accessLumiraDx Oy
OYActiveY-tunnus 2902264-1Pl 44Research and development on medical sciences · NACE 72191Est. 2018— employeeswww.lumiradx.com
Revenue 2025
EUR 0
EBITDA margin
—
Equity ratio
—
Financial strength
Net profit 2025
EUR -59K
-3371% vs 2024
| Revenue | EUR 0 | — |
| EBITDA | EUR -69K | — |
| Net profit | EUR -59K | -3371% |
| Total assets | EUR 0 | -100% |
| Equity | EUR 264K | — |
| Employees | — | — |
Legal name
LumiraDx Oy
Y-tunnus number
2902264-1
Legal form
Osakeyhtiö
NACE code
72191 · Research and development on medical sciences
Founded
8. maaliskuuta 2018
Share capital
EUR 2 500
Employees
—
VAT registered
No
Audit selected
No
Last report
2025-05-21
Financial year
January – December
Signatory rights
Selvitystilan aikana selvitysmies yksin
Company purpose
Yhtiön toimiala on lääketieteelliseen diagnostiikkaan ja terveyteen liittyvien IT-palveluiden kehittäminen, myynti ja jakelu. Lisäksi yhtiö voi omistaa ja hallita kiinteistöjä ja arvopapereita ja käydä niillä kauppaa sekä harjoittaa konsernin sisällä lainanotto- ja lainanantotoimintaa sekä antaa konsernin sisällä avustuksia.
Address
Pl 44
Phone
+3580942455506
Website
www.lumiradx.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 3 | 0 | 21 | 0 | 0 |
| Staff expenses | −86 | −0 | −116 | −2 | −0 |
| EBITDA | 2 | 0 | 3 | 0 | −69 |
| Depreciation & amort. | −1 | −0 | −2 | −0 | −0 |
| EBIT | 0 | 0 | 0 | 0 | −69 |
| Net financials | −0 | 0 | −1 | 0 | 0 |
| Profit before tax | 0 | 0 | −0 | 0 | −69 |
| Tax | −0 | −0 | −1 | −3 | −10 |
| Net profit | 0 | — | 0 | 2 | −59 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 153 | 0 | 68 | 60 | 0 |
| Equity | 125 | 0 | 61 | 0 | 264 |
| Long-term debt | — | 0 | 0 | 0 | 0 |
| Short-term debt | 28 | 0 | 0 | 0 | 320 |
| Total debt | 28 | 0 | 7 | 0 | 320 |
EBITDA margin
-6911300.0%
This company
15.8%
Market median
-43742505% vs market
20212025
Equity ratio
26351400.0%
This company
38.2%
Market median
+68982623% vs market
20212025
Return on equity
-22.4%
This company
18.4%
Market median
-222% vs market
20212025
Net profit margin
-5911300.0%
This company
8.1%
Market median
-72979112% vs market
20212025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
-1.00×
This company
0.62×
Market median
+261% vs market
20212025
- Annual report 2025Filed via PRH / YTJ · Period 2025-01-01 – 2025-05-21
- Annual report 2024Filed via PRH / YTJ · Period 2024-09-25 – 2024-12-31
- Annual report 2023Filed via PRH / YTJ · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via PRH / YTJ · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via PRH / YTJ · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
BE Liquidator | Liquidator | 2025 |
| Former (1) | ||
ET Deputy Chief Executive Officer | Deputy Chief Executive Officer | 2020 – 2023 |
| Name | Role | Member since |
|---|---|---|
| Former (3) | ||
| Board of Directors | 2021 – 2025 | |
| Board of Directors | 2018 – 2021 | |
| Chairperson | 2018 – 2025 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of LumiraDx Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Elvira Turnev | Deputy Chief Executive Officer | 0 companies |
| Björn Eric Christer Gillberg | Liquidator | 0 companies |
| Peter Fröhlich | Board of Directors | 0 companies |
| Veronique Yvonne Ameye | Board of Directors | 0 companies |
| David Walton | Chairperson | 0 companies |